Earnings summaries and quarterly performance for MAXCYTE.
Executive leadership at MAXCYTE.
Board of directors at MAXCYTE.
Research analysts who have asked questions during MAXCYTE earnings calls.
Julie Simmonds
Panmure Liberum
3 questions for MXCT
ML
Matthew Larew
William Blair & Company
3 questions for MXCT
Also covers: AMED, ATR, DNA +10 more
BS
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
2 questions for MXCT
Also covers: ABCL, ABSI, ARWR +19 more
CW
Chad Wiatrowski
TD Cowen
2 questions for MXCT
Also covers: BLFS, CDXS, CTKB +4 more
Mark Massaro
BTIG, LLC
2 questions for MXCT
Also covers: ADPT, AKYA, BLLN +19 more
MH
Matthew Hewitt
Craig-Hallum Capital Group LLC
2 questions for MXCT
Also covers: ACET, APYX, BHST +21 more
RW
Rohan Walcott
Stifel, Nicolaus & Company
2 questions for MXCT
DA
Daniel Arias
Stifel, Nicolaus & Company, Incorporated
1 question for MXCT
Also covers: A, AVTR, CDXS +15 more
Hannah Hefley
Stephens
1 question for MXCT
Also covers: AZTA, MASS, TECH
JJ
Jacob Johnson
Stephens Inc.
1 question for MXCT
Also covers: AZTA, CDMO, CDXS +11 more
ML
Matt Larew
William Blair & Co.
1 question for MXCT
Also covers: AMED, MRVI, RGEN +6 more
PC
Paul Cuddon
Deutsche Numis
1 question for MXCT
Also covers: INDV
Recent press releases and 8-K filings for MXCT.
MaxCyte Announces Preliminary Q4 and Full Year 2025 Financial Results
MXCT
Earnings
Guidance Update
Demand Weakening
- MaxCyte, Inc. announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025.
- For Q4 2025, core revenue is expected to be between $6.6 million and $6.7 million, and Strategic Platform License (SPL) program-related revenue between $0.4 million and $0.6 million.
- For the full year 2025, core revenue is expected to be between $29.5 million and $29.6 million, and SPL program-related revenue between $3.3 million and $3.5 million.
- Total cash, cash equivalents, and investments as of December 31, 2025, are expected to be approximately $155.6 million.
- CEO Maher Masoud stated that 2025 was a challenging year but the company expects to return to revenue growth in the second half of 2026.
Jan 12, 2026, 9:45 PM
MaxCyte Announces Preliminary Q4 and Full Year 2025 Financial Results
MXCT
Earnings
Guidance Update
Demand Weakening
- MaxCyte expects preliminary unaudited core revenue for the fourth quarter ended December 31, 2025, to be between $6.6 million and $6.7 million, and for the full year 2025, between $29.5 million and $29.6 million.
- Strategic Platform License (SPL) program-related revenue is anticipated to be between $0.4 million and $0.6 million for Q4 2025 and between $3.3 million and $3.5 million for the full year 2025.
- The company expects to have approximately $155.6 million in total cash, cash equivalents, and investments as of December 31, 2025.
- CEO Maher Masoud stated that 2025 was a challenging year due to a difficult macro environment and rationalization of programs by some SPL customers, but preliminary core revenue was in line with guidance. He also highlighted that the company is entering 2026 with substantial cash, reduced annual burn, and expects to return to revenue growth in the second half of the year.
Jan 12, 2026, 1:05 PM
MaxCyte Discusses Strategic Focus, SecureDx Integration, and Financial Outlook
MXCT
CFO Change
M&A
Product Launch
- MaxCyte recently announced a CFO transition and an operational restructuring, reducing its employee count to 89-90 from over 50 pre-COVID, to focus on core scientific, engineering, commercial, and FAS teams.
- The acquisition of SecureDx earlier this year aims to engage customers earlier in the development cycle for safety assessments of gene editing therapies. Additionally, a new ExPERT platform extension product, targeting earlier research stages, will commercially launch early next year, expected to contribute to revenue in the second half of 2026.
- MaxCyte has implemented cost savings of $17 million-$19 million annually, projecting a cash burn of $10 million-$15 million for next year with minimal growth. Gross margins, historically around 80%, are expected to return to 84%-85% as revenue grows.
- The company anticipates minimal growth in the first half of 2026 due to lease rationalization, with a pickup in the second half driven by core business, SecureDx, the new product, and global expansion.
Nov 19, 2025, 2:00 PM
MaxCyte Discusses Strategic Focus, SecureDx Integration, and 2026 Outlook
MXCT
CFO Change
M&A
Product Launch
- MaxCyte has undergone a CFO transition and an operational restructuring, reducing its employee count to 89-90 from over 50 pre-COVID, aiming for a more focused scientific, engineering, commercial, and FAS team.
- The company acquired SecureDx earlier this year, which provides assays for gene editing off-target effect nomination, helping to understand safety and engaging customers earlier in the development cycle. This acquisition is seen as a significant growth area with FDA validation.
- Despite macro headwinds from customer program rationalization, MaxCyte continues to sign 3-5 Strategic Platform Licenses (SPLs) annually (4 this year, 5 last year) and is seeing increased instrument placements, seeding the market for future growth.
- MaxCyte plans to commercially launch a new product early next year, an extension of its ExPERT electroporation platform, targeting earlier research phases to expand customer reach and contribute meaningful revenue in the second half of 2026.
- The company has implemented cost savings of $17 million to $19 million annually, expecting a cash burn of $10 million to $15 million next year, with a path to profitability driven by core business growth, milestones, and royalties.
Nov 19, 2025, 2:00 PM
MaxCyte Discusses Strategic Focus, New Product, and 2026 Outlook
MXCT
CFO Change
M&A
Product Launch
- MaxCyte recently completed an operational restructuring, bringing its employee count to 89-90, and announced a CFO transition where Doug Swirsky will serve as an advisor until a replacement is found.
- The company acquired SecureDx earlier this year, which offers gene editing off-target effect nomination assays, enabling earlier customer engagement and receiving FDA validation for its technology.
- A new product, an extension of the ExPERT electroporation platform, is set for commercial launch early next year, targeting earlier research phases and expected to contribute meaningful revenue in the second half of next year.
- MaxCyte expects minimal growth in the first half of 2026 due to prior program rationalization and lease adjustments, but anticipates a pickup in growth in the second half of 2026, leading to overall core growth for the year.
Nov 19, 2025, 2:00 PM
MXCT Reports Q3 2025 Financial Results, Announces Workforce Reduction and CFO Transition
MXCT
Earnings
Guidance Update
Layoffs
CFO Change
- MaxCyte reported total revenue of $6.8 million for Q3 2025, a decrease from $8.2 million in Q3 2024, with core revenue at $6.4 million. The gross margin for Q3 2025 was 77%.
- The company implemented a 34% global workforce reduction, reducing its full-time employee headcount to 89, which is expected to result in $17 million to $19 million in annualized savings.
- MaxCyte reiterated its 2025 guidance, expecting core revenue to be flat to a 10% decline compared to 2024, and SPL program-related revenue to be approximately $5 million. The company anticipates ending 2025 with $152 million to $155 million in cash, cash equivalents, and investments.
- CFO Doug Swersky will transition from his role in the first half of 2026, and a search process has been initiated to identify a successor.
Nov 12, 2025, 9:30 PM
MaxCyte Reports Q3 2025 Financial Results and Reaffirms Full-Year Guidance
MXCT
Earnings
Guidance Update
Demand Weakening
- MaxCyte reported total revenue of $6.8 million for Q3 2025, comprising $6.4 million in core business revenue and $0.4 million in Strategic Platform License (SPL) Program-related revenue.
- For the third quarter of 2025, the company posted a net loss of $12.4 million and an Adjusted EBITDA loss of $10.0 million.
- As of September 30, 2025, MaxCyte's total cash, cash equivalents, and investments stood at $158.0 million.
- MaxCyte reiterated its full-year 2025 guidance, projecting core revenue to be flat to a 10% decline compared to 2024, and SPL Program-related revenue to be approximately $5 million. The company anticipates ending 2025 with $152 million to $155 million in total cash, cash equivalents, and investments.
Nov 12, 2025, 9:13 PM
MaxCyte Reports Preliminary Q3 2025 Financial Results and Reiterates Full Year Guidance
MXCT
Earnings
Guidance Update
Demand Weakening
- MaxCyte reported preliminary unaudited total revenue of $6.8 million for the third quarter ended September 30, 2025, which included $6.4 million in core business revenue and $0.4 million in Strategic Platform License (SPL) Program-related revenue.
- The company's gross margin for Q3 2025 was $5.2 million (77%), with a Non-GAAP adjusted gross margin of 81%.
- MaxCyte reiterated its full-year 2025 revenue guidance, expecting core revenue to be flat to a 10% decline compared to 2024, and SPL Program-related revenue to be approximately $5 million for the year.
- As of September 30, 2025, total cash, cash equivalents, and investments were $158.0 million, with an expectation to end 2025 with $152 million to $155 million.
Nov 5, 2025, 10:24 PM
MaxCyte Reports Preliminary Q3 2025 Results and Reiterates Full-Year Guidance
MXCT
Earnings
Guidance Update
Accounting Changes
- MaxCyte announced preliminary third quarter 2025 total revenue of $6.8 million and a gross margin of $5.2 million (77%).
- As of September 30, 2025, the company reported $158.0 million in total cash, cash equivalents, and investments.
- The company reiterated its 2025 revenue guidance, expecting core revenue to be flat to a 10% decline compared to 2024, and SPL Program-related revenue to be approximately $5 million for the year.
- MaxCyte rescheduled its Q3 2025 financial results release and conference call to allow for additional time to review technical accounting matters related to goodwill and long-lived assets impairment testing.
Nov 5, 2025, 1:05 PM
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio
MXCT
New Projects/Investments
- MaxCyte has signed a Strategic Platform License (SPL) agreement with Moonlight Bio, a preclinical-stage biotechnology company focused on developing T cell therapies for solid tumors.
- Moonlight Bio will utilize MaxCyte's Flow Electroporation® technology and ExPERT™ platform for the scalable development and manufacturing of its T cell therapy pipeline.
- Under the SPL, MaxCyte will receive annual licensing fees and program-related revenue in exchange for granting Moonlight Bio non-exclusive research, clinical, and commercial rights to its technology.
Oct 6, 2025, 12:05 PM
Quarterly earnings call transcripts for MAXCYTE.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more